ParaPRO: Innovations in Life Sciences

Welcome to ParaPRO
ParaPRO is a Specialty Pharmaceutical Company created in 2002 to acquire, develop, and commercialize proprietary products in focused high potential markets.

Information on Natroba™ (spinosad) Topical Suspension 0.9%.

Current ParaPRO News

Newest Head Lice Treatment Now Available to Meet Strong Demand
Natroba™ (spinosad) Topical Suspension, 0.9% Now Available in U.S. Pharmacies

Read the full press release >>

ParaPRO Announces Medicaid Therapeutic Committee Recommendation in Indiana for Natroba™
Read the full press release >>

The American Academy of Pediatrics released their Updated Head Lice Report in the online version of Pediatrics.
Key points include a call to abandon school No Nit Policies , pediatricians are encouraged to take an active role in diagnosis and providing information, diagnosis needs to be confirmed before treatment and treatments should have a clinical record of efficacy and safety for consideration.
Full story/Press Release >>

New Study in the Journal PediatricsĀ® Reports Results Showing Superior Efficacy of Spinosad Head Lice Treatment as Compared to Permethrin
Full story/Press Release >>


Current Head Lice News
American Academy of Pediatrics (AAP) policy on treating head lice
Full story >>

Ask your doctor if Natroba™ Topical Suspension is right for you or your child.

Natroba™ Topical Suspension is a pediculicide indicated for the topical treatment of head lice infestations in patients six (6) months of age and older.

Natroba™ Topical Suspension should be used in the context of an overall lice management program:
  • Wash (in hot water) or dry clean all recently worn clothing, hats, used bedding and towels
  • Wash personal care items such as combs, brushes, and hair clips in hot water
A fine-toothed comb or special nit comb may be used to remove dead lice and nits.

Natroba™ Topical Suspension contains benzyl alcohol and is not recommended for use in neonates and infants below the age of 6 months. Systemic exposure to benzyl alcohol has been associated with serious adverse reactions and death in neonates and low birth-weight infants. Most common adverse events were: application site redness (3%), eye redness (2%) and application site irritation (1%).

Consult the Patient Information, Full Prescribing Information and your doctor for more complete information on Natroba™ Topical Suspension.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.